中文簡介

醫(yī)學(xué)化學(xué)通訊歡迎在藥物化學(xué)和相關(guān)藥物發(fā)現(xiàn)科學(xué)方面的重要研究和評論文章。我們接受通訊和全紙風(fēng)格的文章。在醫(yī)學(xué)化學(xué)通訊上發(fā)表的研究論文必須比以前發(fā)表的論文有顯著的進(jìn)步，或者帶來新的想法或結(jié)果，這些想法或結(jié)果可能會對他們的領(lǐng)域產(chǎn)生強大的影響。期刊范圍內(nèi)的領(lǐng)域包括：新型化學(xué)或生化實體的設(shè)計、合成和生物評價。為了適合發(fā)表，這些必須表現(xiàn)出顯著的潛力，作為新的藥物制劑，工具，探針或潛在的藥物。對已知化學(xué)或生物化學(xué)實體的修改，可使對它們的結(jié)構(gòu)-活性關(guān)系有更大的了解，改善它們的性質(zhì)或提供其他有重要價值的信息，例如，為已知的試劑確定新目標(biāo)。常規(guī)的修改很少或沒有改進(jìn)，不適合醫(yī)學(xué)通訊。注意，只有在明確的陽性對照和陰性對照的情況下進(jìn)行新化合物或現(xiàn)有化合物作為藥理學(xué)試劑進(jìn)行測試的研究，并在原稿中參考現(xiàn)有最有效的藥劑，才會考慮這些研究。這種類型的研究應(yīng)該包括一個明確定義和假設(shè)驅(qū)動的復(fù)合設(shè)計理論。潛在的抗菌藥物應(yīng)進(jìn)行細(xì)胞毒性和對非相關(guān)病原體的活性測試。在更廣泛的化學(xué)和生物科學(xué)(例如，使合成化學(xué)，化學(xué)生物學(xué)，組學(xué)科學(xué)，結(jié)構(gòu)生物學(xué)，納米科學(xué))的新方法和技術(shù)應(yīng)用于藥物發(fā)現(xiàn)。計算研究是受歡迎的，因為它們大大提高了藥物化學(xué)知識。使用已建立的計算方法進(jìn)行的研究應(yīng)包括原始預(yù)測，并應(yīng)附以新的實驗數(shù)據(jù)，以驗證所作的預(yù)測。報道新的計算方法的研究必須通過與實驗數(shù)據(jù)的比較來證明其在藥物化學(xué)中的應(yīng)用。不清楚地將所得結(jié)果與實驗數(shù)據(jù)聯(lián)系起來的計算研究，或者沒有顯示出實用價值的計算研究(或者實用價值不太可能顯著促進(jìn)該領(lǐng)域的發(fā)展)，不適合醫(yī)學(xué)化學(xué)通訊。請注意，沒有實驗數(shù)據(jù)的對接研究不適合發(fā)表在雜志上。研究化合物的分子結(jié)構(gòu)對藥物動力學(xué)行為和藥效學(xué)的影響。請注意，只專注于藥物傳遞劑的研究不適合在醫(yī)學(xué)化學(xué)通訊發(fā)表。為了幫助編輯和審稿人評估每一篇投稿的重要性，我們要求所有投稿作者在投稿時提供一份簡要的重要性陳述。這應(yīng)該包括一句話來總結(jié)手稿中最重要的發(fā)現(xiàn)，第二句話來說明為什么這是該領(lǐng)域的重大進(jìn)展。這一重要性聲明應(yīng)具體側(cè)重于所提交研究報告的重要性，而不是該領(lǐng)域的重要性。

投稿網(wǎng)址：http://mc.manuscriptcentral.com/rsc

英文簡介

MedChemComm welcomes significant research and review articles in medicinal chemistry and related drug discovery science. We accept both communication and full paper style articles.Research articles published in MedChemComm must show a significant advance on previously published work, or bring new thinking or results which will potentially have a strong impact in their field.Examples of areas within the journal's scope are:Design, synthesis and biological evaluation of novel chemical or biochemical entities. To be suitable for publication these must exhibit significant potential as new pharmacological agents, tools, probes or potential drugs.Modifications of known chemical or biochemical entities that result in a significantly greater understanding of their structure-activity relationships, an improvement of their properties or which provide other information of significant value, for example, the identification of a new target for a known agent. Routine modifications with minimal or no improvement are not suitable for MedChemComm.Note that studies where new or existing compounds are tested as pharmacological agents will only be considered if they are carried out in the presence of clear positive and negative controls and reference is made in the manuscript to the most powerful existing agents. Studies of this type should include a clearly defined and hypothesis-driven compound design rationale. Potential antimicrobial agents should be tested for cytotoxicity and activity against non-related pathogens.Novel methodologies and technologies in the broader chemical and biological sciences (for example, enabling synthetic chemistry, chemical biology, -omics sciences, structural biology, nanoscience) with application to drug discovery.Computational studies are welcome where they significantly advance medicinal chemistry knowledge. Studies that use established computational methods should include an original prediction and be accompanied by new experimental data which validates the prediction made. Studies which report novel computational methodology must demonstrate its use in medicinal chemistry through comparison with experimental data. Computational research that does not clearly relate the results obtained to experimental data or which has no demonstrated utility (or where the utility is unlikely to significantly advance the field) is not suitable for MedChemComm. Please note that docking studies presented without experimental data are not suitable for publication in the journal.Studies which examine the effect of the molecular structure of a compound on pharmacokinetic behaviour and pharmacodynamics.Note that studies which focus solely on drug delivery agents are not suitable for publication in MedChemComm.To help editors and referees assess the significance of each submitted manuscript we ask all authors on submission to provide a brief statement of significance. This should contain one sentence to summarise the most important finding(s) in the manuscript and a second sentence to say why this is a significant advance in the field. This significance statement should focus specifically on the importance of the piece of research being submitted, rather than the importance of the field.